Hostname: page-component-76fb5796d-wq484 Total loading time: 0 Render date: 2024-04-27T13:00:52.979Z Has data issue: false hasContentIssue false
  • English
  • Français

Selective Histamine H1 Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines

Published online by Cambridge University Press:  07 November 2014

Stephen M. Stahl
Get access Rights & Permissions [Opens in a new window]

Extract

Numerous “antihistamines” as well as various psychotropic medications with antihistamine properties are widely utilized to treat insomnia. Over-the-counter sleep aids usually contain an antihistamine and various antidepressants and antipsychotics with antihistamine properties have sedative-hypnotic actions. Although widely used for the treatment of insomnia, many agents that block the histamine H1 receptor are also widely considered to have therapeutic limitations, including the development of next-day carryover sedation, as well as problems with chronic use, such as the development of tolerance to sedative-hypnotic actions and weight gain. Although these clinical actions are classically attributed to blockade of the H1 receptor, recent findings with H1 selective agents and H1 selective dosing of older agents are challenging these notions and suggest that some of the clinical limitations of current H1-blocking agents at their currently utilized doses could be attributable to other properties of these drugs, especially to their simultaneous actions on muscarinic, cholinergic, and adrenergic receptors. Selective H1 antagonism is emerging as a novel approach to the treatment of insomnia, without tolerance, weight gain, or the need for the restrictive prescription scheduling required of other hypnotics.

Type
Trends in Psychopharmacology
Information
CNS Spectrums , Volume 13 , Issue 12 , December 2008 , pp. 1027 - 1038
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Stahl, SM. Stahl's Essential Psychopharmacology. 3rd ed. New York, NY: Cambridge University Press; 2008.Google Scholar
2.Saper, CB, Chou, TC, Scammell, TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001;24:726–731.Google Scholar
3.Mignot, E, Taheri, S, Nishino, S. Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. Nat Neurosci. 2002;5:1071–1075.CrossRefGoogle ScholarPubMed
4.John, J, Wu, M-F, Boehmer, LN, Siegel, JM. Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. Neuron. 2004;42:619–634.Google Scholar
5.Brown, RE, Stevens, DR, Haas, HL. The physiology of brain histamine. Prog Neuorbiol. 2001;63:637–672.Google Scholar
6.Ramesh, V, Thakkar, MM, Strecker, RE, Basheer, R, McCarley, RW. Wakefulness-inducing effects of histamine in the basal forebrain of freely moving rats. Behav Brain Res. 2004;152:271–278.CrossRefGoogle ScholarPubMed
7.Strecker, RE, Nalwalk, J, Dauphin, LJ, et al.Extracellular histamine levels in the feline preoptic/anterior hypothalamic area during natural sleep-wakefulness and prolonged wakefulness: an in vivo microdialysis study. Neuroscience. 2002;113:663–670.Google Scholar
8.Ishizuka, T, Yamamoto, Y, Yamatodani, A. The effect of orexin-A and -B on the histamine release in the anterior hypothalamus in rats. Neurosci Lett. 2002;323:93–96.Google Scholar
9.Eriksson, KS, Sergeeva, O, Brawn, RE, Haas, HL. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci. 2001;21:9273–9279.CrossRefGoogle ScholarPubMed
10.Nishino, S, Fujiki, N, Ripley, B, Sakurai, E, Kato, M, Watanabe, T, Mignot, E, Yanai, K. Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci Lett. 2001;313:125–128.Google Scholar
11.Huang, ZL, Qu, WM, Li, WD, et al.Arousal effect or orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A. 2001;98:9965–9970.Google Scholar
12.Bayer, L, Eggermann, E, Serafin, M, et al.Orexins (hypocretins) directly excite tuberomammillary neurons. Eur J Neurosci. 2001;14:1571–1575.Google Scholar
13.Shigemoto, Y, Fujii, Y, Shinomiya, K, Kamei, C. Participation of histaminergic H1 and noradrenergic alpha 1 receptors in orexin A-induced wakefulness in rats. Brain Res. 2004;1023:121–125.Google Scholar
14.Stevens, DR, Kuramasu, A, Haas, HL. GABA-B receptor mediated control of GABAergic inhibition in rat histaminergic neurons in vitro. Eur J Neurosci. 1999;11:1148–1154.Google Scholar
15.Nofzinger, EA, Buysse, DJ, Germain, A, Price, JC, Miewald, JM, Kupfer, DJ. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry. 2004;161:2126–2129.Google Scholar
16.Quach, TT, Duchemin, AM, Rose, C, Schwartz, JC. In vivo occupation of cerebral histamine H1-receptors evaluated with 3H-mepyramine may predict sedative properties of psychotropic drugs. Eur J Pharmacol. 1979;60:391–392.Google Scholar
17.Philippu, A, Prast, H. Importance of histamine in modulatory processes, locomotion and memory. Behav Brain Res. 2001;124:151–159.Google Scholar
18.Bacciottini, L, Passani, MB, Mannaioni, PF, Blandina, P. Interactions between histaminergic and cholinergic systems in learning and memory. Behav Brain Res. 2001;124:183–194.CrossRefGoogle ScholarPubMed
19.Benarroch, EE, ed. Brain Neurosciences with Clinical Implications. Oxford, UK: Butterworth-Heinemann; 2006.Google Scholar
20.Haas, H, Paulina, P. Histamine. Nat Rev Neurosci. 2003;4:121–130.Google Scholar
21.Hill, SJ, Ganellin, CR, Timmerman, H, et al.Classification of histamine receptors. Pharmacol Rev. 1997;49:253–278.Google Scholar
22.Line, JS. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev. 2000;4:471–503.Google Scholar
23.Cusack, B, Nelson, A, Richelson, E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacol (Berl). 1994;114:559–564.Google Scholar
24.Tatsumi, M, Groshan, K, Blakely, RD, Richelson, E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340:249–258.CrossRefGoogle ScholarPubMed
25.Richelson, E, Souder, T. Binding of antipsychotic drugs to human brain receptors focus on newer generations compounds. Life Sci. 2000;68:29–39.Google Scholar
26.Cohrs, S, Rodenbeck, A, Guan, Z, et al.Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacol (Berl). 2004;174:421–429.Google Scholar
27.James, SP, Mendelson, WB. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry. 2004;65:752–755.Google Scholar
28.Kanba, S, Richelson, E. Histamine H1 receptors in human brain labelled with 3H-doxepin. Brain Res. 1984;304:1–7.Google Scholar
29.Taylor, JE, Richelson, E. High-affinity binding of 3H-doxepin to histamine H1-receptors in rat brain: possible identification of a subclass of histamine H1-receptors. Eur J Pharmacol. 1982;78:279–285.Google Scholar
30.Kano, M, Fukudo, S, Tashiro, A, et al.Decreased histamine H1 receptor binding in the brain of depressed patients. Eur J Neurosci. 2004;20:803–810.Google Scholar
31.Yanai, K, Ryu, JH, Watanabe, T, et al.Histamine H1-receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol. 1995;116:1649–1655.Google Scholar
32.Yanai, K, Watanabe, T, Yokoyama, H, et al.Histamine H1 receptors in human brain visualized in vivo by 11C-doxepin and positron emission tomography. Neurosci Lett. 1992;137:145–148.Google Scholar
33.Tashiro, M, Sakurada, Y, Iwabuchi, K, et al.Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness and brain histamine H1-receptor occupancy using 11 C-doxepin positron emission tomography. J Clin Pharmacol. 2004;8:890–900.Google Scholar
34.Tashiro, M, Mochizuki, H, Sakurada, Y. et al.Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. Br J Clin Pharmacol. 2006;61:16–26.Google Scholar
35.Scavone, JM, Greenblatt, DJ, Harmatz, JS, Engelhardt, N, Shader, RI. Pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers. J Clin Pharmacol. 1998;38:603–609.Google Scholar
36.Roth, T, Rogowski, R, Hull, S, et al.Efficacy and safety of doxepin 1,3 and 6 mg in adults with primary insomnia. Sleep. 2007;30:1555–1561.Google Scholar
37.Scharf, M, Rogowski, R, Hull, S, et al.Efficacy and safety of doxepin 1,3 and 6 mg in elderly patients with primary insomnia. J Clin Psychiatry. 2008;69:1557–1564.Google Scholar
38.Schwartz, H, Hull, S, Seiden, D, et al.Efficacy and safety of doxepin 6 mg in a model of transient insomnia. Sleep. 2007;30:A266. Abstract #0779.Google Scholar
39.Roth, T, Durrence, H, Gotfried, M, et al.Efficacy and safety of doxepin 1 and 3 mg in a 3-month trial of elderly adults with chronic insomnia. Sleep. 2008;31:A230. Abstract 0701.Google Scholar
40.Richardson, GS, Roehrs, TA, Rosenthal, L, Koshorek, G, Roth, T. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol. 2002;22:511–515.CrossRefGoogle ScholarPubMed
41.Hajak, G, Rodenbeck, A, Voderholzer, U, et al.Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry. 2001;62:453–463.CrossRefGoogle ScholarPubMed
42.Lankford, A, Hull, S, Scharf, M, et al. Efficacy and safety of doxepin 3 and 6 mg in adults with primary insomnia. Presented at: 21st Annual Meeting of the Associated Professional Sleep Societies; June 9-14, 2007; Minneapolis, MN.Google Scholar
43.Wirshing, DA, Wirshing, WC, Kysar, L, et al.Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60:358–363.CrossRefGoogle ScholarPubMed
44.Lader, M. Introduction to Psychopharmacology. Kalamazoo, MI: Upjohn; 1980.Google Scholar
45.Bourin, M, Briley, M. Sedation, an unpleasant, undesirable, and potentially dangerous side-effect of many psychotropic drugs. Hum Psychopharm. 2004;19:135–139.Google Scholar
46.Richtand, NM, Woods, SC, Berger, SP, Strakowski, SM. D3 dopamine receptor, behavioral sensitization and psychosis. Neurosci Biobehav Rev. 2001;25:427–443.CrossRefGoogle ScholarPubMed
47.Richelson, E. Psychotherapeutic drugs, histamine H1 and muscarinic acetylcholine receptors. In: Yamamura, , Olsen, , Usdin, , eds. Psychopharmacology and Biochemistry of Neurotransmitter Receptors. Huntington, NY: Elsevier; 1980;263–277.Google Scholar